changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Study shows patients treated with TheraSphere® maintain quality of life throughout 90 day post-treatment period
BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology
BTG plc (LSE: BTG), an international specialist healthcare company, today announced that the first patient in Malaysia was treated with TheraSphere™ – a transarterial radioembolisation (TARE) therapy, which targets primary liver cancer and metastatic colorectal cancer with a powerful dose of radiation while minimising exposure to healthy tissue.
BTG plc (LSE: BTG), an international specialist healthcare company, today announced the launch of the BETA™ Radiation Safety Programme, a new initiative designed to reduce the risk of radiation exposure when performing selective internal radiation therapy (SIRT) with Y90 microspheres. Developed in collaboration with global experts, including Professor Jacob Kamen of the Mount Sinai Medical Center, the βETA™ Radiation Safety Programme analyses current practise and exposure risk, and provides recommendations to improve safety for healthcare professionals and patients.
BTG plc (LSE: BTG), the specialist healthcare company, today announced the first treatment of patients in South Korea with TheraSphere® – a treatment for primary liver cancer and metastatic colorectal cancer that delivers powerful radiation to tumour cells and minimises the exposure to healthy tissue.
BTG plc (LSE: BTG), a global specialist healthcare company and Mirada Medical Ltd, a medical imaging software company, today announced an important collaboration to develop dosimetry software solutions to optimise radioembolisation therapy with TheraSphere®.
BTG plc (LSE: BTG), the specialist healthcare company, today announced the treatment of the first patient in Singapore with TheraSphere®, a treatment for primary liver cancer and metastatic colorectal cancer, specifically engineered to deliver powerful doses of radiation to the tumour while minimising exposure to normal tissue.
BTG and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), are pleased to announce that BTG has become a major supporter of ESIRonline, CIRSE’s extensive database of educational materials on interventional radiology.
BTG plc, today announces that the National Institute for Health and Care Excellence (NICE) has issued guidance recommending the use of Selective Internal Radiation Therapy (SIRT), which includes TheraSphere®, for patients with liver cancer across the NHS.
On 23 May 2013, BTG plc (BTG), the specialist healthcare company, announced that it had entered into an agreement to buy the Targeted Therapies division of Nordion, Inc. (the Acquisition).
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com